28 lugio 2014 –
Pubblicati ieri sul New England Journal of Medicine, una delle riviste scientifiche di maggior rilevo i risultati dello studio CLARINET, che confermano il ruolo degli analoghi della somatostatina nella terapia dei tumori neuroendocrini ben differenziati.
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors — The New England Journal of Medicine, one of the most influential medical journals in the world, has just published important clinical trial results showing that Somatuline (lanreotide) “achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CLARINET, an investigational Phase III randomized, double-blind, placebo-controlled study of the antiproliferative effects of Somatuline was conducted in 48 centers across 14 countries.” Read the article here